Please assess the completion status of the following clinical trial:

Trial Title: A Safety Study of XL019 in Adults With Myelofibrosis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* The subject has primary myelofibrosis (PMF), post-polycythemia vera MF, or post-essential thrombocythemia MF and requires therapy, including subjects who have received prior MF-directed therapy and relapsed or subjects with refractory disease; or if newly diagnosed, then with intermediate or high risk according to the Lille scoring system.~* The subject is unwilling to undergo or is not a candidate for peripheral stem cell/bone marrow transplant.~* The subject is ≥18 years old.~* The subject has an Eastern Cooperative Oncology Group (ECOG) performance status of ≤2.~* The subject has adequate organ function.~* The subject has the capability of understanding the informed consent document and has signed the informed consent document.~* Sexually active subjects (male and female) must use medically acceptable methods of contraception during the course of the study.~* Female subjects of childbearing potential must have a negative pregnancy test at screening.~* The subject has had no diagnosis of malignancy or evidence of other malignancy for 2 years prior to screening for this study (except non-melanoma skin cancer or in situ carcinoma of the cervix).~Exclusion Criteria:~* The subject has uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, hypertension, symptomatic congestive heart failure, unstable angina pectoris, myocardial infarction within 3 months, or cardiac arrhythmias.~* The subject is pregnant or breastfeeding.~* The subject is known to be positive for the human immunodeficiency virus (HIV).~* The subject is unable or unwilling to abide by the study protocol or cooperate fully with the investigator or designee.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).